Lily Zou, Degron Therapeutics CEO

Take­da en­ters hot mol­e­c­u­lar glue space in up to $1.2B pact with De­gron

Take­da is adding the pop­u­lar “mol­e­c­u­lar glue” ap­proach to its R&D ca­pa­bil­i­ties in an up to $1.2 bil­lion col­lab­o­ra­tion with a young biotech.

The Japan­ese …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.